0XOD.L - UroGen Pharma Ltd.

LSE - LSE Delayed Price. Currency in USD

UroGen Pharma Ltd.

400 Alexander Park
Princeton, NJ 08540
United States
646 768 9780

Full-time employees194

Key executives

NameTitlePayExercisedYear born
Ms. Elizabeth A. BarrettPres, CEO & Director1.12MN/A1962
Mr. Dong KimChief Financial Officer546.68kN/A1977
Mr. Jason Drew SmithGen. Counsel, Chief Compliance Officer & Corp. Sec.717.58kN/A1972
Vincent I. PerroneSr. Director of Investor RelationsN/AN/AN/A
Mr. Eric Van ZantenSr. Director of CommunicationsN/AN/AN/A
Dr. Sari Prutchi-Sagiv Ph.D.Marketing DirectorN/AN/AN/A
Dr. Marina KonortyExec. VP of R&D and Technical OperationsN/AN/AN/A
Dr. Mark P. Schoenberg M.D.Chief Medical OfficerN/AN/A1958
Mr. Jeffrey Bova M.B.A.Chief Commercial OfficerN/AN/AN/A
Mr. James Ottinger R.ph.Exec. VP of Regulatory Affairs & QualityN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Corporate governance

UroGen Pharma Ltd.’s ISS governance QualityScore as of 1 June 2023 is 6. The pillar scores are Audit: 8; Board: 3; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.